Hacioglu, SibelBilen, YusufEser, AliSivgin, SerdarGurkan, EmelYildirim, RahsanKeskin, Ali2025-05-102025-05-1020150278-02321099-106910.1002/hon.21772-s2.0-84954543319https://doi.org/10.1002/hon.2177https://hdl.handle.net/20.500.14720/15001Kuku, Irfan/0000-0001-6126-0816; Tombak, Anil/0000-0002-7195-1845; Gurkan, Emel/0000-0002-3060-4054; Yildirim, Rahsan/0000-0002-5717-3936; Dogu, Mehmet Hilmi/0000-0001-7237-2637In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd.eninfo:eu-repo/semantics/closedAccessHairy Cell LeukemiaTurkeyTreatmentCladribinSurvivalArticle334Q2Q319219825393847WOS:000368248400011